Edition:
India

Quidel Corp (QDEL.OQ)

QDEL.OQ on NASDAQ Stock Exchange Global Select Market

45.87USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$45.87
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
113,600
52-wk High
$49.45
52-wk Low
$20.43

Chart for

About

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $1,436.60
Shares Outstanding(Mil.): 33.44
Dividend: --
Yield (%): --

Financials

BRIEF-Quidel Receives 510(K) Clearance For Quickvue Influenza A+B Test

* QUIDEL RECEIVES 510(K) CLEARANCE FOR QUICKVUE INFLUENZA A+B TEST, ASSAY MEETS FDA'S CLASS II RIDT REQUIREMENTS

14 Feb 2018

BRIEF-Quidel Receives FDA Clearance And Clia Waiver For Its Point-Of-Care Sofia® 2 Instrument

* QUIDEL RECEIVES FDA CLEARANCE AND CLIA WAIVER FOR ITS POINT-OF-CARE SOFIA® 2 INSTRUMENT FOR USE WITH SOFIA STREP A+ ASSAY Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

22 Dec 2017

BRIEF-Quidel Says Confident In Validity Of Supply Agreement With Beckman Coulter To Sell BNP Assay Assets

* QUIDEL CONFIDENT IN LEGAL STRENGTH AND VALIDITY OF SUPPLY AGREEMENT WITH BECKMAN COULTER TO SELL BNP ASSAY ASSETS

27 Nov 2017

BRIEF-Quidel Corp reports Q3 GAAP loss per share $0.16

* Q3 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S

02 Nov 2017

BRIEF-Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA

* Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA

23 Oct 2017

BRIEF-Quidel gets FDA nod for Solana Assay molecular diagnostic test

* Quidel receives FDA clearance for its Solana RSV + hMPV Assay

17 Oct 2017

BRIEF-Quidel Corp says ‍on Oct 6, co entered into credit agreement​

* Quidel corp says ‍on Oct 6, co entered into credit agreement​ - sec filing

07 Oct 2017

BRIEF-QUIDEL ANNOUNCES EARLY TERMINATION OF HART-SCOTT-RODINO WAITING PERIOD ON DEAL FOR ALERE'S ASSAY BUSINESS

* QUIDEL ANNOUNCES EARLY TERMINATION OF THE HART-SCOTT-RODINO WAITING PERIOD FOR ITS PENDING ACQUISITION OF ALERE’S TRIAGE® B-TYPE NATURIETIC PEPTIDE (BNP) ASSAY BUSINESS RUN ON BECKMAN COULTER ANALYZERS

28 Sep 2017

BRIEF-Quidel announces revised agreement for pending acquisition of Alere’s business

* Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers

18 Sep 2017

Earnings vs. Estimates